Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice*

• Main Authors: Hong Du, Terri L. Cameron, Stephen J. Garger, Gregory P. Pogue, Lee A. Hamm, Earl White, Kathleen M. Hanley, Gregory A. Grabowski
• Format: Article
• Language: English
• Published: Elsevier 2008-08-01
• Series: Journal of Lipid Research
• Subjects: cholesteryl esters; triglyceride; plant-produced human enzyme; macrophage; pharmacokinetics; pharmacodynamics
• Online Access: http://www.sciencedirect.com/science/article/pii/S0022227520346824

Lysosomal acid lipase (LAL) is an essential enzyme that hydrolyzes triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Genetic LAL mutations lead to Wolman disease (WD) and cholesteryl ester storage disease (CESD). An LAL-null (lal−/−) mouse model resembles human WD/CESD with storage of CEs and TGs in multiple organs. Human LAL (hLAL) was expressed in Nicotiana benthamiana using the GENEWARE® expression system (G-hLAL). Purified G-hLAL showed mannose receptor-dependent uptake into macrophage cell lines (J774E). Intraperitoneal injection of G-hLAL produced peak activities in plasma at 60 min and in the liver and spleen at 240 min. The t1/2 values were: ∼90 min (plasma), ∼14 h (liver), and ∼32 h (spleen), with return to baseline by ∼150 h in liver and ∼200 h in spleen. Ten injections of G-hLAL (every 3 days) into lal−/− mice produced normalization of hepatic color, decreases in hepatic cholesterol and TG contents, and diminished foamy macrophages in liver, spleen, and intestinal villi. All injected lal−/− mice developed anti-hLAL protein antibodies, but suffered no adverse events. These studies demonstrate the feasibility of using plant-expressed, recombinant hLAL for the enzyme therapy of human WD/CESD with general implications for other lysosomal storage diseases.